Tislelizumab and Lenvatinib Show Efficacy in Advanced Rare Kidney Cancer
A phase 2 clinical trial shows that combining tislelizumab and lenvatinib produces high objective response rates in patients with advanced ...
A phase 2 clinical trial shows that combining tislelizumab and lenvatinib produces high objective response rates in patients with advanced ...
In a phase I trial of Chinese patients with advanced solid tumors resistant to prior immunotherapy, combining ceralasertib with durvalumab ...
A case report in BMC Gastroenterology describes sustained hepatitis B surface antigen seroclearance in a patient with esophageal and gastric ...
A case report describes fulminant sintilimab-associated myocarditis progressing to complete atrioventricular block despite a preserved ejection fraction, with suspected myositis–myasthenia ...
A case report details the diagnostic and therapeutic challenges of managing immune checkpoint inhibitor myocarditis in a patient with coexisting ...
A study of 3,243 Japanese patients found that observed fixed-dose nivolumab billing was a median of 89,540 yen higher per ...
A case report documents curative lung resection 144 days after a patient survived grade 4 immune checkpoint inhibitor-associated myocarditis during ...
A case report describes a man with giant unresectable hepatocellular carcinoma whose inferior vena cava tumor thrombus regressed completely after ...
A case report describes cholestatic liver injury during atezolizumab therapy for EGFR-mutant combined small cell lung cancer, with AMA-M2 positivity ...
A case report describes a woman with extensive-stage small-cell lung cancer who developed a cerebrospinal fluid anti-Hu-positive neurological syndrome during ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine